Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey

被引：18

作者：

Lip, Gregory Y. H. ^{[1
]}

Bongiorni, Maria Grazia ^{[2
]}

Dobreanu, Dan ^{[3
]}

Lewalter, Thorsten ^{[4
]}

Hastrup Svendsen, Jesper ^{[5
,6
]}

Blomstrom-Lundqvist, Carina ^{[7
]}

机构：

[1] Univ Birmingham, Ctr Cardiovasc Sci, City Hosp Birmingham, Birmingham B18 7DH, W Midlands, England

[2] Univ Hosp Pisa, Cardiol Dept 2, Pisa, Italy

[3] Univ Med & Pharm, Dept Cardiol, Ctr Cardiovasc Dis & Transplant, Targu Mures, Romania

[4] Isar Heart Ctr Munich, Munich, Germany

[5] Univ Copenhagen, Rigshosp, Ctr Heart, Dept Cardiol, DK-2100 Copenhagen, Denmark

[6] Danish Natl Res Fdn, Ctr Cardiac Arrhythmia, Copenhagen, Denmark

[7] Uppsala Univ, Dept Cardiol, Inst Med Sci, Uppsala, Sweden

来源：

EUROPACE | 2013年 / 15卷 / 10期

关键词：

Atrial fibrillation; Anticoagulation; Guidelines; Warfarin; New oral anticoagulants; Apixaban; Dabigatran; Rivaroxaban; Stroke; EP wire; EHRA survey; ADHERENT ANTITHROMBOTIC TREATMENT; NET CLINICAL BENEFIT; DABIGATRAN ETEXILATE; RANDOMIZED EVALUATION; RISK STRATIFICATION; CONSENSUS DOCUMENT; CATHETER ABLATION; SYSTEMIC EMBOLISM; MODELING ANALYSIS; THERAPY;

D O I：

10.1093/europace/eut292

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The purpose of this European Heart Rhythm Association (EHRA) survey was to assess clinical practice in relation to stroke prevention in atrial fibrillation (AF), particularly into the use of novel oral anticoagulants (NOACs) for stroke prevention, among members of the EHRA electrophysiology (EP) research network. In this EP Wire survey, we have provided some insights into current practice in Europe for the use of NOACs for stroke prevention in AF. There were clear practice differences evident, and also the need for greater adherence to the guidelines, especially since guideline adherent management results in better outcomes in AF.

引用

页码：1526 / 1532

页数：7

共 34 条

[1]

Apostolakis S, 2013, CHEST, DOI [10.1378/chest.13-0054, DOI 10.1378/CHEST.13-0054]

[2] Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study [J].

Banerjee, Amitava ;

Lane, Deirdre A. ;

Torp-Pedersen, Christian ;

Lip, Gregory Y. H. .

THROMBOSIS AND HAEMOSTASIS, 2012, 107 (03) :584-589

[3] Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis [J].

Bin Abdulhak, Aref A. ;

Khan, Abdur Rahman ;

Tleyjeh, Imad M. ;

Spertus, John A. ;

Sanders, Susan U. ;

Steigerwalt, Kristy E. ;

Garbati, Musa A. ;

Bahmaid, Reem A. ;

Wimmer, Alan P. .

EUROPACE, 2013, 15 (10) :1412-1420

[4]

Camm AJ, 2012, EUROPACE, V14, P1385, DOI [10.1093/eurheartj/ehs253, 10.1093/europace/eus305]

[5] Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial [J].

Dans, Antonio L. ;

Connolly, Stuart J. ;

Wallentin, Lars ;

Yang, Sean ;

Nakamya, Juliet ;

Brueckmann, Martina ;

Ezekowitz, Michael ;

Oldgren, Jonas ;

Eikelboom, John W. ;

Reilly, Paul A. ;

Yusuf, Salim .

CIRCULATION, 2013, 127 (05) :634-640

[6] Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial [J].

Dewilde, Willem J. M. ;

Oirbans, Tom ;

Verheugt, Freek W. A. ;

Kelder, Johannes C. ;

De Smet, Bart J. G. L. ;

Herrman, Jean-Paul ;

Adriaenssens, Tom ;

Vrolix, Mathias ;

Heestermans, Antonius A. C. M. ;

Vis, Marije M. ;

Tijsen, Jan G. P. ;

van 't Hof, Arnoud W. ;

ten Berg, Jurrien M. .

LANCET, 2013, 381 (9872) :1107-1115

[7] Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial [J].

Eikelboom, John W. ;

Wallentin, Lars ;

Connolly, Stuart J. ;

Ezekowitz, Mike ;

Healey, Jeff S. ;

Oldgren, Jonas ;

Yang, Sean ;

Alings, Marco ;

Kaatz, Scott ;

Hohnloser, Stefan H. ;

Diener, Hans-Christoph ;

Franzosi, Maria Grazia ;

Huber, Kurt ;

Reilly, Paul ;

Varrone, Jeanne ;

Yusuf, Salim .

CIRCULATION, 2011, 123 (21) :2363-U72

[8] Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting A North-American perspective [J].

Faxon, David P. ;

Eikelboom, John W. ;

Berger, Peter B. ;

Holmes, David R. ;

Bhatt, Deepak L. ;

Moliterno, David J. ;

Becker, Richard C. ;

Angiolillo, Dominick J. .

THROMBOSIS AND HAEMOSTASIS, 2011, 106 (04) :572-584

[9]

Fitzmaurice DA, 2005, BRIT MED J, V331, P1057, DOI 10.1136/bmj.38618.580903.AE

[10] Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study [J].

Friberg, Leif ;

Rosenqvist, Marten ;

Lip, Gregory Y. H. .

EUROPEAN HEART JOURNAL, 2012, 33 (12) :1500-+

← 1 2 3 4 →